Latest Healthcare News

Lumos Diagnostics has increased live FebriDx sites to 215 and moved two additional top 100 US urgent care groups into network rollout across more than 40 sites. Two further health-system-owned groups are validating the test across more than 45 sites, but the announcement does not disclose contract values or guaranteed purchase volumes.

PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.

Regal Asian Investments delivered a 3.2% net portfolio return in August, lifting its 12-month performance to 36.4% despite continued volatility across Asian equities. The listed investment company’s shares ended the month at a 14.3% discount to post-tax NTA, while its buy-back and fully franked dividend continued.

HealthCo Healthcare & Wellness REIT says lenders have backed the proposed transfer of operations at 10 Healthscope hospitals owned by HCW and its unlisted fund. The transaction remains subject to customary approvals, but Healthscope has paid all rent due through September 2026.

Pacific Edge is positioning Cxbladder for a Medicare-led recovery, but the company remains loss-making with NZ$7.8 million in net cash after a difficult FY26. The investment case now turns on final US coverage, test volumes and whether the enlarged balance sheet can carry the business to scale.

Synertec has identified ANSTO as the client behind its $45.5 million engineering contract, with about $36 million of revenue expected during the first 26 months. The project could improve FY27 revenue, but the company has not yet revised its guidance.

Proteomics International has begun a controlled release of two Promarker diagnostic tests through Healius in Western Australia and the Northern Territory. National commercial sales are targeted for Q2 FY27, but uptake and revenue remain difficult to estimate at this early stage.

Australian United Investment Company’s profit surged after its merger with Diversified United Investment, but the headline result was dominated by a one-off acquisition gain. Underlying profit rose 19.9%, while AUI expanded its portfolio to about A$3.1 billion and declared fully franked dividends totalling 28 cents per share.

Marlin Global delivered a 3.0% gross performance return in August, beating its benchmark as software holdings rebounded sharply. The Fisher Funds-managed portfolio is also preparing to exit some investments and add businesses in three sectors.

Kingfish’s adjusted NAV rose 1.2% in August, broadly matching the NZX benchmark as Vista, Fisher & Paykel Healthcare and Delegat delivered the strongest portfolio gains. The fund still trades at a 7.5% discount to NAV, while its one-year shareholder return remains negative.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Cleo Diagnostics has appointed Bio-Techne’s CLIA-certified U.S. laboratory Asuragen to run pivotal clinical validation for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to generate the evidence supporting a planned FDA 510(k) submission in the first half of calendar 2027.